Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706508 | 0.83 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3671684 | 0.81 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6672567 | 0.81 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8784754 | 0.81 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2130015 | 0.79 | CA1 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9326106 | 0.78 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29771456 | 0.78 | CA2 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL19468259 | 0.78 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL30948566 | 0.78 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8784464 | 0.78 | CA1 (0.57) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074869-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-03-06 | — | — | US | disclosed |
| EP-4245750-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| CN-112225673-B | Amino combretastatin derivative and application thereof | 义乌市华耀医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114085184-A | Biphenyl derivative containing cyclopropane structure and preparation method and application thereof | 中山大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-112390802-A | Pyrrolopyrazole derivative, preparation method and medical application thereof | 上海美迪西生物医药股份有限公司 | 2021-02-23 | — | — | CN | disclosed |
| CN-112225673-A | Amino combretastatin derivative and application thereof | 义乌市华耀医药科技有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-1611116-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | Neuromed Technologies, Inc. (CA) | 2006-01-04 | — | — | EP | disclosed |
| US-6943168-B2 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES INC. (CA) | 2005-09-13 | — | — | US | disclosed |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-30 | — | — | US | disclosed |
| WO-2004089922-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | disclosed |
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-0696280-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMA (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994026735-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | CA1 288/4885CA2 77/4885CA7 1595/4885 |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | CA1 288/4885CA2 77/4885CA7 1595/4885 |
| US-20250074869-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | TUBB3, TUBB6, TUBA3C | CA1 867/4885CA2 554/4885CA7 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.